| HLX10 |
MSI-H Solid Malignant Tumor
|
Phase II
|
A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy
|
| HLX20 |
Advanced Soild Tumours
|
Phase I
|
A Phase I Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients with Advanced Solid Tumors
|
| HLX22 |
Soild Tumours
|
Phase I
|
Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
|
| HLX12 |
Healthy Male Subjects
|
Phase I
|
A Phase I Study Comparinge Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects
|
| HLX07 |
Advanced Soild Tumours
|
Phase Ib/II
|
The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined with Chemotherapy in Advanced Solid Tumors
|
